Network News
The National Medical Products Administration (NMPA) in China has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic device in China. It is intended as a companion diagnostic to identify patients with MSI-high (MSI-H) solid tumors for treatment with KEYTRUDA® (pembrolizumab), the anti-PD-1 therapy from Merck & Co., Inc., […]
read more
aimed analytics GmbH highlighted in deutsche-startups.de
5 neue Startups: ONOX, aimed analytics, Recarbox, FORMIC, showroom.fm Es ist wieder soweit – neue Startups stehen in den Startlöchern! Hier sind einige spannende junge Unternehmen, die man kennen sollte. Heute werfen wir einen Blick auf diese Neugründungen: ONOX, aimed analytics, Recarbox, FORMIC und showroom.fm. deutsche-startups.de stellt heute erneut eine Auswahl junger Startups vor, die […]
read more
BioMed X Launches First Research Project in Partnership with the Government of Barbados to Advance Therapy of Early Diabetic Kidney Disease
Bridgetown, Barbados, January 27, 2026 – BioMed X, a leading innovation hub for pharma, today announced the launch of its first research project in partnership with the Government of Barbados and with support from the European Union’s PharmaNext Programme. The new global call for research proposals, entitled “AI-Enabled Therapy of Early Diabetic Kidney Disease in Barbados,” addresses one of the most pressing and underexplored […]
read more
Natural and safe contraception: New research consortium aims to enable more reliable home testing
The German Federal Ministry of Research, Technology, and Space is providing €2.8 million in funding for an interdisciplinary scientific consortium with the aim of making cycle apps for determining a woman’s fertile and infertile days significantly more reliable by taking biological markers into account. Researchers from the universities and university hospitals of Düsseldorf, Hamburg, and […]
read more
When Artificial Intelligence Creates Stronger Emotional Closeness than a Human
Heidelberg and Freiburg researchers study interaction with AI chatbots Humans can build emotional closeness to artificial intelligence (AI) – under certain conditions even more strongly than to another human being. This has been shown by studies conducted by Prof. Dr Bastian Schiller from Heidelberg University’s Institute of Psychology in cooperation with colleagues from the University […]
read more
Using AI to Retrace the Evolution of Genetic Control Elements in the Brain
Researchers map evolutionary changes in the developing mammalian cerebellum Artificial intelligence allows tracing the evolution of genetic control elements in the developing mammalian cerebellum. An international research team led by biologists from Heidelberg University as well as the Vlaams Instituut voor Biotechnologie and KU Leuven (Belgium) has now developed advanced AI models that can predict […]
read more
A double-edged sword: Chronic cellular stress promotes liver cancer – but at the same time renders tumors vulnerable to immunotherapy
A key molecular mechanism drives the growth of liver cell cancer while simultaneously suppressing the body’s immune response to the tumor. This has now been published in the journal Nature by a team led by researchers from the German Cancer Research Center (DKFZ), the University Hospital of Tübingen, and the Sanford Burnham Prebys Medical Discovery […]
read more
AI learns from animals: New approach to improve surgical imaging
Scientists at the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD), and Mannheim University Medical Center (UMM) are presenting a method that enables artificial intelligence (AI) to learn how to transfer medical image data from animals to humans. This “xeno-learning” could help make surgical procedures safer and more precise in the future – without […]
read more
Heidelberg Pharma Received Development Milestone Payment from Partner Takeda
Ladenburg, Germany, 29 January 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it has received a milestone payment under the terms of its license agreement with partner Takeda based on the achievement of a clinical development milestone for Takeda’s investigational medicine that utilizes […]
read more
